The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial resultsGail D. Lewis Phillips(Gene Therapy Laboratory), Eunpi Cho(Unknown)Nature CommunicationsJanuary 11, 202410.1038/s41467-023-44533-zCited by 43SaveCiteExport RISWatch citationsRelated PapersIdentification of Heregulin, a Specific Activator of p185 <sup>erbB2</sup>|Science|1992|964LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity|Nature|2022|385